• +353-1-416-8900(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
Septic Shock - Pipeline Review, H2 2012 Product Image

Septic Shock - Pipeline Review, H2 2012

  • Published: October 2012
  • 62 pages
  • Global Markets Direct

Septic Shock – Pipeline Review, H2 2012

Summary

Global Markets Direct’s, 'Septic Shock - Pipeline Review, H2 2012', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Septic Shock, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Septic Shock. Septic Shock - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Septic Shock.
- A review of the Septic Shock products under development by companies and universities/research institutes based on information derived READ MORE >

2
List of Tables 5
List of Figures 6
Introduction 7
REPORT COVERAGE 7
Septic Shock Overview 8
Therapeutics Development 9
An Overview of Pipeline Products for Septic Shock 9
Septic Shock Therapeutics under Development by Companies 11
Septic Shock Therapeutics under Investigation by Universities/Institutes 12
Late Stage Products 14
Comparative Analysis 14
Mid Clinical Stage Products 15
Comparative Analysis 15
Early Clinical Stage Products 16
Comparative Analysis 16
Pre-Clinical Stage Products 17
Comparative Analysis 17
Septic Shock Therapeutics – Products under Development by Companies 18
Septic Shock Therapeutics – Products under Investigation by Universities/Institutes 19
Companies Involved in Septic Shock Therapeutics Development 20
Baxter International Inc. 20
Novo Nordisk A/S 21
Cytokine PharmaSciences, Inc. 22
MetrioPharm AG 23
Ikaria Inc. 24
Septic Shock – Therapeutics Assessment 25
Assessment by Monotherapy Products 25
Assessment by Combination Products 26
Assessment by Route of Administration 27
Assessment by Molecule Type 29
Drug Profiles 31
IK-6003 - Drug Profile 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
TREM-1 - Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
thiamine - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
serum albumin - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
epinephrine - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
Methylene Blue + Nitric Oxide - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 37
hydrocortisone acetate - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
terlipressin - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
argipressin - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
recombinant Human Activated Protein C - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
Recombinant Human Activated Protein C + Hydrocortisone + Fludrocortisone - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 43
levocarnitine - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
glucose-insulin-potassium - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
glutamine - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
ketamine hydrochloride - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
simvastatin - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
MIF Inhibitors - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
ardeparin sodium - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
hydrocortisone acetate - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
Hypertonic Saline + Terlipressin - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
hetastarch - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
Anti-MIF Antibody - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
Anti-MIF Receptor Technology Platform - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
levocarnitine - Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
Septic Shock Therapeutics – Drug Profile Updates 57
Septic Shock Therapeutics – Discontinued Products 58
Septic Shock Therapeutics - Dormant Products 59
Septic Shock – Product Development Milestones 60
Featured News & Press Releases 60
Apr 09, 2010: XOMA To Present Data On XOMA 052 At American Association of Cancer Research Annual Meeting 60
Appendix 61
Methodology 61
Coverage 61
Secondary Research 61
Primary Research 61
Expert Panel Validation 61
Contact Us 62
Disclaimer 62

List of Tables
Number of Products Under Development for Septic Shock, H2 2012 9
Products under Development for Septic Shock – Comparative Analysis, H2 2012 10
Number of Products under Development by Companies, H2 2012 11
Number of Products under Investigation by Universities/Institutes, H2 2012 13
Comparative Analysis by Late Stage Development, H2 2012 14
Comparative Analysis by Mid Clinical Stage Development, H2 2012 15
Comparative Analysis by Early Clinical Stage Development, H2 2012 16
Comparative Analysis by Pre-Clinical Stage Development, H2 2012 17
Products under Development by Companies, H2 2012 18
Products under Investigation by Universities/Institutes, H2 2012 19
Baxter International Inc., H2 2012 20
Novo Nordisk A/S, H2 2012 21
Cytokine PharmaSciences, Inc., H2 2012 22
MetrioPharm AG, H2 2012 23
Ikaria Inc., H2 2012 24
Assessment by Monotherapy Products, H2 2012 25
Assessment by Combination Products, H2 2012 26
Assessment by Stage and Route of Administration, H2 2012 28
Assessment by Stage and Molecule Type, H2 2012 30
Septic Shock Therapeutics – Drug Profile Updates 57
Septic Shock Therapeutics – Discontinued Products 58
Septic Shock Therapeutics – Dormant Products 59

List of Figures
Number of Products under Development for Septic Shock, H2 2012 9
Products under Development for Septic Shock – Comparative Analysis, H2 2012 10
Products under Development by Companies, H2 2012 11
Products under Investigation by Universities/Institutes, H2 2012 12
Late Stage Products, H2 2012 14
Mid Clinical Stage Products, H2 2012 15
Early Clinical Stage Products, H2 2012 16
Pre-Clinical Stage Products, H2 2012 17
Assessment by Monotherapy Products, H2 2012 25
Assessment by Combination Products, H2 2012 26
Assessment by Route of Administration, H2 2012 27
Assessment by Stage and Route of Administration, H2 2012 28
Assessment by Molecule Type, H2 2012 29
Assessment by Stage and Molecule Type, H2 2012 30

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos